Tirzepatide ke "insulinotropic polypeptide" (GIP) e itšetlehileng ka tsoekere e habeli le glucagon-like peptide-1 (GLP-1) receptor agonists. Mokhoa oa eona o habeli o ikemiselitse ho ntlafatsa secretion ea insulin, ho hatella ho lokolloa ha glucagon, ho lieha ho tsoa ka mpeng, le ho ntlafatsa ho khora, ho fana ka mokhoa o felletseng oa kalafo bakeng sa mofuta oa 2 lefu la tsoekere (T2DM) le botenya.
Liphuputso tsa Bohlokoa Lithutong tsa Tleliniki
1. Taolo ea Glycemic
Ka har'a tse ngataHLOMPHOLiteko tsa kliniki tsa mohato oa 3, tirzepatide e bontšitsoetaolo e phahameng ea glycemicha e bapisoa le li-antidiabetic tse seng li ntse li le teng, ho kenyelletsa semaglutide le insulin degludec.
-
Ho bolela ho fokotseha ha HbA1c: ho fihlela ho−2.4%ho tloha qalong ka mor'a libeke tse 40-52.
-
Karolo e phahameng ea bankakarolo e fihletsoengHbA1c <6.5%, ho kopana kapa ho fetisa lipehelo tsa ADA.
-
Lintlafatso tse kholo tsa ho itima lijo tsa tsoekere ea plasma le maemo a tsoekere ea postprandial li ile tsa bonoa.
2. Phokotso ea Boima
Tirzepatide e lula e hlahisoaho theola boima ba 'mele ho nang le moelelo oa bongaka le ho itšetlehile ka tekanyoho batho ba nang le lefu la tsoekere le bao e seng ba lefu la tsoekere.
-
Ho bakuli ba T2DM: ka karolelano ho fokotseha ha boima ba 'mele ho tloha ho7-12 lik'hilograma.
-
Ho batho bao e seng ba lefu la tsoekere (teko ea SURMOUNT-1):
-
10 mg le 15 mg litekanyetso li lebisitse ho15-22% e bolela ho lahleheloa ke boima ba 'mele, ho bapisoa kapa ho feta litekanyo tsa ho buuoa ka bariatric.
-
-
Boholo ba barupeluoa ba fihletse bonyane5–10%phokotso ya boima.
3. Lintlafatso tsa Cardiometabolic
Kalafo ea Tirzepatide e boetse e ntlafalitse litekanyetso tse pharalletseng tsa metabolic:
-
Phokotsoka triglycerides, LDL-C, le k'holeseterole eohle.
-
Ea eketsehaka HDL-C.
-
Bohlokoaho fokotseha ha khatello ea mali ea systolic le diastolic.
-
Ntlafatso ea kutloisiso ea insulin le ts'ebetso ea β-cell.
4. Tšireletseho le Mamello
Boemo ba polokeho bo ne bo lumellana le liphekolo tse ling tse thehiloeng ho incretin:
-
Liketsahalo tse mpe tse atileng haholo: matšoao a ka mpeng ho isa ho a itekanetseng (ho nyekeloa ke pelo, ho hlatsa, letšollo).
-
Keketseho e tlase ea hypoglycemia, haholo ha e sebelisoa le insulin kapa sulfonylureas.
-
Ha ho mathata a maholo a tšireletso a hlokometsoeng liphellong tsa pelo.
5. Maikutlo a Mechini
Tirzepatide e ikhethangagonism ea li-receptor tse pelie holisa litsela tsa GIP le GLP-1:
-
GIP ts'ebetsonge ntlafatsa tlhahiso ea insulin e itšetlehileng ka tsoekere 'me e ka ntlafatsa metabolism ea lisele tsa adipose.
-
Ts'ebetso ea GLP-1e thusa ho fokotsa takatso ea lijo le ho liehisa ho tsoa ka mpeng.
-
Tsa bonaphello ea synergistice lebisa taolong e ntlafetseng ea tsoekere ka phokotso e matlafalitsoeng ea boima ba 'mele ha e bapisoa le lisebelisoa tsa tsela e le 'ngoe.
Qetello
Tirzepatide e emela akatleho kalafong ea metabolic, ho fanakatleho e sa lebelloang ho taolo ea glycemic le phokotso ea boima ba 'melebakeng sa batho ba nang le lefu la tsoekere la mofuta oa 2 le botenya.
Mochini oa eona oa li-incretin tse peli o fana ka mokhoa o kopaneng o rarollang lisosa tsa ho se sebetse hantle ha metabolism - hyperglycemia, ho hanyetsa insulin le boima ba 'mele bo feteletseng.
Ka lebaka la ts'ebetso ea eona e matla le boemo bo laolehang ba polokeho, tirzepatide e ka hlalosa bocha paradigm ea kalafo ea lefu la tsoekere le taolo ea botenya lilemong tse leshome tse tlang.
Litšupiso
-
Frias JP et al.,New England Journal of Medicine, 2021.
-
Jastreboff AM et al.,New England Journal of Medicine, 2022 (SURMOUNT-1).
-
Ludvik B et al.,Lancet, 2021.
-
Eli Lilly Clinical Data, SURPASS Liteko 1-5.
Nako ea poso: Oct-04-2025